These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 28583342

  • 21. Systematic Review and Meta-analysis of Flibanserin's Effects and Adverse Events in Women with Hypoactive Sexual Desire Disorder.
    Saadat SH, Kabir A, Rahmani K, Panahi Y, Hosseinialhashemi M, Sahebkar A.
    Curr Drug Metab; 2017; 18(1):78-85. PubMed ID: 27784209
    [Abstract] [Full Text] [Related]

  • 22. Flibanserin Efficacy and Safety in Premenopausal Women With Generalized Acquired Hypoactive Sexual Desire Disorder.
    Fisher WA, Pyke RE.
    Sex Med Rev; 2017 Oct; 5(4):445-460. PubMed ID: 28666836
    [Abstract] [Full Text] [Related]

  • 23. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women.
    Clayton AH, Dennerstein L, Pyke R, Sand M.
    Womens Health (Lond); 2010 Sep; 6(5):639-53. PubMed ID: 20887163
    [Abstract] [Full Text] [Related]

  • 24. Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin.
    Simon JA, Clayton AH, Kim NN, Patel S.
    Sex Med; 2022 Feb; 10(1):100476. PubMed ID: 34999484
    [Abstract] [Full Text] [Related]

  • 25. Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder.
    Simon JA, Clayton AH, Goldstein I, Kingsberg SA, Shapiro M, Patel S, Kim NN.
    Sex Med; 2022 Dec; 10(6):100570. PubMed ID: 36400683
    [Abstract] [Full Text] [Related]

  • 26. Effects of Alcohol Administered With Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study.
    Simon JA, Clayton AH, Parish SJ, Apfel SC, Millheiser L.
    J Sex Med; 2020 Jan; 17(1):83-93. PubMed ID: 31735618
    [Abstract] [Full Text] [Related]

  • 27. Weight Loss in Women Taking Flibanserin for Hypoactive Sexual Desire Disorder (HSDD): Insights Into Potential Mechanisms.
    Simon JA, Kingsberg SA, Goldstein I, Kim NN, Hakim B, Millheiser L.
    Sex Med Rev; 2019 Oct; 7(4):575-586. PubMed ID: 31196764
    [Abstract] [Full Text] [Related]

  • 28. Flibanserin and its discontents.
    Aftab A, Chen C, McBride J.
    Arch Womens Ment Health; 2017 Apr; 20(2):243-247. PubMed ID: 27858170
    [Abstract] [Full Text] [Related]

  • 29. Flibanserin and Female Sexual Desire.
    Fantasia HC.
    Nurs Womens Health; 2016 Apr; 20(3):309-14. PubMed ID: 27287358
    [Abstract] [Full Text] [Related]

  • 30. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
    Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, Spana C.
    J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
    [Abstract] [Full Text] [Related]

  • 31. The pharmacodynamic effects of combined administration of flibanserin and alcohol.
    Stevens DM, Weems JM, Brown L, Barbour KA, Stahl SM.
    J Clin Pharm Ther; 2017 Oct; 42(5):598-606. PubMed ID: 28608926
    [Abstract] [Full Text] [Related]

  • 32. Effects of Timing of Flibanserin Administration Relative to Alcohol Intake in Healthy Premenopausal Women: A Randomized, Double-Blind, Crossover Study.
    Simon JA, Clayton AH, Kingsberg SA, Parish SJ, Kim NN, Millheiser L.
    J Sex Med; 2019 Nov; 16(11):1779-1786. PubMed ID: 31522985
    [Abstract] [Full Text] [Related]

  • 33. Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women.
    Pyke RE, Clayton AH.
    J Sex Med; 2019 Dec; 16(12):1885-1894. PubMed ID: 31678098
    [Abstract] [Full Text] [Related]

  • 34. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women.
    Fabre LF, Brown CS, Smith LC, Derogatis LR.
    J Sex Med; 2011 May; 8(5):1411-9. PubMed ID: 21324094
    [Abstract] [Full Text] [Related]

  • 35. Flibanserin: From Bench to Bedside.
    Dooley EM, Miller MK, Clayton AH.
    Sex Med Rev; 2017 Oct; 5(4):461-469. PubMed ID: 28757356
    [Abstract] [Full Text] [Related]

  • 36. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women.
    Rosen RC, Maserejian NN, Connor MK, Krychman ML, Brown CS, Goldstein I.
    Menopause; 2012 Apr; 19(4):396-405. PubMed ID: 22076307
    [Abstract] [Full Text] [Related]

  • 37. Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction.
    Kingsberg SA, Althof SE.
    J Sex Med; 2011 Dec; 8(12):3262-70. PubMed ID: 21883949
    [Abstract] [Full Text] [Related]

  • 38. Flibanserin: First Global Approval.
    Deeks ED.
    Drugs; 2015 Oct; 75(15):1815-22. PubMed ID: 26412054
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of Tribulus Terrestris for the treatment of premenopausal women with hypoactive sexual desire disorder: a randomized double-blinded, placebo-controlled trial.
    Vale FBC, Zanolla Dias de Souza K, Rezende CR, Geber S.
    Gynecol Endocrinol; 2018 May; 34(5):442-445. PubMed ID: 29172782
    [Abstract] [Full Text] [Related]

  • 40. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
    Krapf JM, Simon JA.
    Maturitas; 2009 Jul 20; 63(3):213-9. PubMed ID: 19487090
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.